文献速递胸部肿瘤放疗姑息放疗与转移瘤

大分割胸部放疗后肿瘤组织PD-L1诱导表达:一例病例报告

PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-04-07

报告一例67岁晚期肺腺癌男性患者,初诊PD-L1阴性,2015年接受纵隔肿块姑息性大分割放疗后,2017年活检显示PD-L1肿瘤比例评分达100%。此后接受帕博利珠单抗治疗2年(32周期),所有病灶达部分缓解并维持稳定,末次CT(2020年3月)仍显示持续部分缓解。

要点

  • 大分割胸部放疗后,原PD-L1阴性肿瘤可转为PD-L1高表达(TPS 100%)。
  • 放疗后新发十二指肠转移灶亦检出PD-L1高表达。
  • 帕博利珠单抗治疗2年(32周期)后所有病灶部分缓解并持续稳定。

核心结论

  • 大分割胸部放疗后肿瘤组织PD-L1表达可由阴性转为高阳性(TPS 100%),提示放疗可能诱导PD-L1表达。

研究设计与样本

  • 单例病例报告:67岁男性晚期肺腺癌患者,初诊PD-L1阴性、EGFR及ALK阴性,2014年确诊。

主要发现

  • 患者2014至2017年接受4线姑息化疗后疾病进展。
  • 2015年接受纵隔肿块姑息性大分割放疗以缓解不适和疼痛。
  • 2017年放疗后纵隔肿块活检显示PD-L1转为高阳性,肿瘤比例评分为100%。
  • 2017年因十二指肠穿孔切除的新转移灶亦检出PD-L1高表达。
  • 2017年10月至2019年10月接受帕博利珠单抗治疗2年共32周期,所有病灶达部分缓解并后续稳定。

关键数值与推荐

  • 放疗后纵隔肿块活检PD-L1肿瘤比例评分为100%。
  • 帕博利珠单抗治疗共32周期、持续2年(2017年10月至2019年10月),疗效为部分缓解。
  • 末次CT扫描(2020年3月)显示持续部分缓解。

临床怎么用

  • 对PD-L1阴性且接受过大分割放疗的患者,可考虑放疗后重新活检评估PD-L1状态。
  • 放疗后PD-L1诱导表达可能为后续免疫检查点抑制剂治疗提供依据。

局限性

  • 仅为单例病例报告,无法确立放疗与PD-L1诱导之间的因果关系。
  • 缺乏放疗前后系统性的PD-L1动态检测数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report on a 67-year old male with advanced stage lung adenocarcinoma (initially PD-L1 negative, EGFR and ALK negative) diagnosed in 2014. The patient received 4 lines of palliative chemotherapy from 2014 to 2017, however the disease progressed. In 2015, he also received palliative hypofractionated radiotherapy to a mediastinal mass, which was causing discomfort and pain. Since there was some data, that radiotherapy could induce PD-L1 expression, a new biopsy was taken in 2017 from the irradiated mediastinal mass. Subsequent pathologic report revealed that PD-L1 status was turned to be highly positive, with tumor proportion score of 100%. Similar high expression of PD-L1 was detected in a new metastasis in the duodenum, which was excised due to a duodenal perforation in 2017. From October 2017 to October 2019, the patient had 2-years of treatment (32 courses) with pembrolizumab and has had a positive effect (partial response) on all the lesions and following stabilization of the disease. Currently, this patient is under follow up and he is in a good condition without any complaints. Last CT-scan in March 2020 showed persisting partial response.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Narits J, Tamm H, Jaal J, et al. PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer. Clin Transl Radiat Oncol. 2020. PMID: 32300664. doi:10.1016/j.ctro.2020.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。